Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma

Research output: Contribution to journalArticle

4 Downloads (Pure)

Abstract

Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil™) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.
Original languageEnglish
Pages (from-to)7-11
Number of pages5
JournalBiologics: Targets & Therapy
Volume7
DOIs
Publication statusPublished - 9 Jan 2013

Fingerprint

Asthma
Interleukin-5
Eosinophils
Antibodies, Monoclonal, Humanized
Bone Marrow
Inflammation
reslizumab

Keywords

  • IL-5
  • asthma
  • eosinophil

Cite this

@article{12123d6c27d146f5b329ae02a2066ff2,
title = "Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma",
abstract = "Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil™) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.",
keywords = "IL-5, asthma, eosinophil",
author = "Walsh, {Garry Michael}",
year = "2013",
month = "1",
day = "9",
doi = "10.2147/BTT.S30133",
language = "English",
volume = "7",
pages = "7--11",
journal = "Biologics: Targets & Therapy",
issn = "1177-5475",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma

AU - Walsh, Garry Michael

PY - 2013/1/9

Y1 - 2013/1/9

N2 - Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil™) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.

AB - Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil™) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.

KW - IL-5

KW - asthma

KW - eosinophil

U2 - 10.2147/BTT.S30133

DO - 10.2147/BTT.S30133

M3 - Article

VL - 7

SP - 7

EP - 11

JO - Biologics: Targets & Therapy

JF - Biologics: Targets & Therapy

SN - 1177-5475

ER -